BioVie releases phase 2 trial results for Parkinson's Disease treatment

BioVie releases phase 2 trial results for Parkinson's Disease treatmentПодробнее

BioVie shares latest updates on Alzheimer's and Parkinson's Disease clinical trialsПодробнее

BioVie's Novel Approach in the Battle Against Alzheimer's and Parkinson'sПодробнее

BioVie Pharma Inc announces NE3107 Phase 2 trial has been fully enrolledПодробнее

Hope for Parkinson's and Alzheimer's Patients: An In-Depth Interview with Cuong Do, CEO of BioVie.Подробнее

BioVie: Potential Blockbuster Late-Stage Programs Targeting Alzheimer’s & Parkinson’sПодробнее

Update on Parkinson’s disease clinical trialsПодробнее

Phase III trial update of P2B001 for Parkinson's diseaseПодробнее

BioVie released encouraging findings from a phase 2 trial of their Parkinson's and Alzheimer's drugПодробнее

BioVie: Targeting Parkinson’s Disease with Groundbreaking Neurological TreatmentsПодробнее

Biovie and Parkinson's DiseaseПодробнее

5 year clinical trial results - light therapy for Parkinson's with Dr Brian BicknellПодробнее

BioVie: Developing the First Ever Potentially Effective Drug for Alzheimer’sПодробнее

Learnings from clinical trial failure in Parkinson's diseaseПодробнее

Researchers discover drug that could stop or slow Parkinson's diseaseПодробнее

Enrolling treatment-naive patients in Parkinson’s disease clinical trialsПодробнее

Parkinson's Disease Treatment PipelineПодробнее

The potential of ambroxol in Parkinson’s disease dementia: Phase II trial resultsПодробнее

BioVie recent announcements around Alzheimers and Parkinson's shows encouraging dataПодробнее

BioVie (NASDAQ: BIVI): New solutions for Alzheimer's, Parkinson'sПодробнее